Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest EORTC Stories

2012-03-15 22:49:46

The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma (HCC). The EASL-EORTC guidelines define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC. HCC is the most common form of liver cancer, representing more than 90% of primary liver cancers and an...

2011-11-14 06:00:00

CALGARY, Nov. 14, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that interim results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with gemcitabine (Gemzar(®)) in patients with advanced pancreatic cancer will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is being held in San...

2011-11-11 15:00:00

CALGARY, Nov. 11, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Monday, November 14(th), 2011 at 6:30 a.m. MT (8:30 a.m. ET) to discuss in more depth clinical data being presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference being held in San Francisco, CA from November 12(th) to 16(th), 2011. To access...

2011-11-09 05:00:00

SINGAPORE, Nov. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has named a Clinical Evaluation Management Committee. The committee will act as a semi-independent advisory board, guiding Volition's clinical trial and validation strategy both for European CE Mark and American FDA approval processes. "As we have had very promising results in internal lab testing on small numbers...

2011-11-01 08:00:00

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the presentation of mechanistic studies on Telintra and related analogs at the 2011 Meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. Details of the presentation are as follows: Novel Ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit...

2011-10-24 07:00:00

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, for the diabetes, cancer, dermatology and drug delivery markets, today announced its upcoming poster presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, taking place October 27-29 in Brussels, Belgium. Halozyme's PEGPH20 is a PEGylated form of rHuPH20 that is being evaluated in an ongoing...

2011-10-18 08:00:00

BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 /PRNewswire/ -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than 6,600 patients in 111 institutions across nine countries were enrolled from February 2007 to July 2011 in this...

2011-09-26 05:46:00

OXFORD, England, September 26, 2011 /PRNewswire/ -- EJC App Now Available on the App Store Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of the iPad edition of the European Journal of Cancer (EJC). Starting with the September 2011 issue, all 18 annual issues of the EJC will be available through the EJC App on the App Store. iPad editions feature the same...

2010-11-01 06:30:00

CALGARY, Nov. 1 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering preclinical research with reovirus (REOLYSIN((R))) is available on the European CanCer Organisation (ECCO) website at www.ecco-org.eu. The research is scheduled to be presented at the 22(nd) EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16(th) - 19(th) 2010. The abstract, entitled...

2009-11-16 06:30:00

CALGARY, Nov. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced that a poster presentation covering updated results of a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers will be presented on November 17, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts. The poster presentation is...